Mitchell Sinkler & Starr PA Sells 11,596 Shares of Stryker Co. (NYSE:SYK)

Mitchell Sinkler & Starr PA decreased its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 63.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,743 shares of the medical technology company's stock after selling 11,596 shares during the period. Mitchell Sinkler & Starr PA's holdings in Stryker were worth $2,428,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC bought a new position in shares of Stryker during the 4th quarter valued at approximately $25,000. Dunhill Financial LLC increased its stake in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after purchasing an additional 37 shares during the period. Rakuten Securities Inc. increased its position in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after acquiring an additional 68 shares during the period. Centricity Wealth Management LLC purchased a new position in Stryker during the 4th quarter worth $30,000. Finally, BankPlus Trust Department purchased a new position in shares of Stryker during the fourth quarter valued at $33,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Up 0.4 %

NYSE:SYK traded up $1.63 on Wednesday, hitting $374.93. 686,021 shares of the company's stock traded hands, compared to its average volume of 1,291,468. The firm has a 50-day moving average price of $383.41 and a 200-day moving average price of $374.43. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a market cap of $143.11 billion, a PE ratio of 48.32, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Remove Ads

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the firm posted $3.46 earnings per share. Equities analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.90%. Stryker's dividend payout ratio is currently 43.30%.

Analyst Ratings Changes

SYK has been the topic of a number of recent analyst reports. JMP Securities restated a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. JPMorgan Chase & Co. boosted their price target on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Needham & Company LLC restated a "buy" rating and set a $442.00 target price on shares of Stryker in a research report on Friday, March 21st. Finally, Royal Bank of Canada upped their target price on Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $421.90.

Insider Buying and Selling at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.50% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.